Linzess Labeling Updated Based on New Pediatric Data
The updated label now states that the treatment is contraindicated in patients less than 2 years of age due to the risk of serious dehydration.
Constipation
Study Suggests Limited Efficacy of OTC Meds for Chronic Idiopathic Constipation
Results showed that the majority of patients expressed dissatisfaction with the effect of the OTC agent on constipation and CIC-specific abdominal symptoms.
Generic Version of Amitiza Now Available
The Company has begun shipping both the 8mcg and 24mcg capsules; the capsules are supplied in 60-count bottles.
Opioid-Induced Constipation Management Guidelines
Recommendations from the American Gastroenterological Association (AGA) for the medical management of opioid-induced constipation (OIC).
Motegrity Approved for Chronic Idiopathic Constipation in Adults
Shire announced that the Food and Drug Administration (FDA) has approved Motegrity (prucalopride) tablets for the treatment of adults with chronic idiopathic constipation (CIC).
New Treatment for Opioid-Induced Constipation Approved
The Company’s petition for the descheduling of Symproic is currently being evaluated by the Drug Enforcement Agency (DEA).
Antipsychotic Found to Significantly Slow Bowel Motility
Patients treated with the antipsychotic clozapine were found to have delayed colonic transit that was 4 times longer than normal, findings from a new study published in EBioMedicine reported.
Review: Constipation Diagnosis and Treatments
When choosing a treatment for chronic idiopathic constipation (CIC) or opioid-induced constipation (OIC), it should be based on cost and efficacy, a review published in JAMA described.
Ani Approved for Polyethylene Glycol 3350 Powder
Ani Pharmaceuticals announced that the Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for Polyethylene Glycol 3350 Powder for Oral Solution.
